Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 9/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.44 |
| ▸ | MELK | Q14680 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25227474 | 0.94 | MAPK10 (0.59) | MAPK10MAPK8MAPK9MELKMMP12 | |
| SCHEMBL25238874 | 0.83 | USP30 (0.49) | MAPK10MAPK8MAPK9MELKNTRK1 | |
| SCHEMBL25237287 | 0.83 | USP30 (0.49) | MAPK10MAPK8MAPK9MELKNTRK1 | |
| SCHEMBL25230167 | 0.83 | USP30 (0.49) | MAPK10MAPK8MAPK9MELKNTRK1 | |
| SCHEMBL25551275 | 0.78 | MMP12 (0.45) | MAPK10MAPK8MAPK9MELKNTRK1 | |
| SCHEMBL25201439 | 0.78 | MMP12 (0.45) | MELKMMP12 | |
| SCHEMBL25233639 | 0.77 | USP30 (0.51) | MAPK10MAPK8MAPK9MELKNTRK1 | |
| SCHEMBL25550292 | 0.76 | MAPK10 (0.51) | MAPK10MAPK8MAPK9MELKMMP12 | |
| SCHEMBL25243811 | 0.76 | SLC6A4 (0.46) | — | |
| SCHEMBL25206604 | 0.76 | SLC6A4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049776-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR A SYSTEMIC TREATMENT OF DISEASES AND CONDITIONS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2025-02-13 | — | — | US | disclosed |
| EP-4183449-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049776-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR A SYSTEMIC TREATMENT OF DISEASES AND CONDITIONS | BECN1, TFEB, SQSTM1 | MAPK10 821/4885MAPK8 1633/4885MAPK9 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.